



Company Overview

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Petaluma, California, with manufacturing operations in both the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results

Aug 13 2019, 5:35 PM EDT

Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule

Jul 12 2019, 9:00 AM EDT

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results

Jul 8 2019, 4:03 PM EDT

Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	9.05m
Last Price	\$6.80
52-Week	\$4.8473 - \$25.200001

09/20/2019 02:18 PM EDT

Investor Relations

T: 707-559-7380
ir@sonomapharma.com

Management Team

Bubba Sandford

CEO/CFO

Bruce Thornton

Executive Vice President

Robert Northey Ph.D

Director of Research and Development

Sonoma Pharmaceuticals, Inc.

1129 North McDowell Blvd.
Petaluma, CA 94954

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.